Version 1
: Received: 13 April 2024 / Approved: 15 April 2024 / Online: 15 April 2024 (13:51:27 CEST)
How to cite:
Kassab, M.M.S. Production of Myxopyronin a Antibiotic from Different Soil Environments in Egypt. Preprints2024, 2024040975. https://doi.org/10.20944/preprints202404.0975.v1
Kassab, M.M.S. Production of Myxopyronin a Antibiotic from Different Soil Environments in Egypt. Preprints 2024, 2024040975. https://doi.org/10.20944/preprints202404.0975.v1
Kassab, M.M.S. Production of Myxopyronin a Antibiotic from Different Soil Environments in Egypt. Preprints2024, 2024040975. https://doi.org/10.20944/preprints202404.0975.v1
APA Style
Kassab, M.M.S. (2024). Production of Myxopyronin a Antibiotic from Different Soil Environments in Egypt. Preprints. https://doi.org/10.20944/preprints202404.0975.v1
Chicago/Turabian Style
Kassab, M.M.S. 2024 "Production of Myxopyronin a Antibiotic from Different Soil Environments in Egypt" Preprints. https://doi.org/10.20944/preprints202404.0975.v1
Abstract
Background:
Antibiotic resistance is an overwhelming serious difficulty globally. This necessitates the exploration of novel sources of antibiotics to overcome this challenge.
Aim of the study:
Bacterial Myxopyronin A production from various soil environments
Egypt; as well as testing its antimicrobial activity in preclinical animal testing and randomized human clinical trials phases 1/2.
Type of the study:
Screening experimental study.
Methodology:
Different soil environments in Egypt were screened for the growth of bacterial isolates producing Myxopyronin A as an antimicrobial agent. Purification of Myxopyronin A was performed via reversed-phase HPLC. Paper disc diffusion assay, as well as the Broth dilution technique, were exploited to assess the invitro antimicrobial and minimum inhibitory concentration( MIC) of the test antibiotic. Furthermore, in vivo antimicrobial spectrum, adverse drug reactions, and pharmacokinetics were detected during animal model testing stages and human randomized clinical trials phases 1/2.
Results:
From the culture supernatant of the Myxobacterium Myxococcus fulvus 124B02 which was the predominant soil bacterial isolate grown on the Casein yeast peptone plate, Myxopyronin A was produced. The test antibiotic blocked the growth of many Gram +ve bacteria with MICs less than 100 mcg/ ml. In contrast, it inhibited the growth of a few Gram -ve bacteria such as Escherichia coli at MICs greater than 100 mcg/ ml. On the other hand, Eukaryotic cells such as fungal and human cells were not affected. Prokaryotic DNA-dependant-RNA polymerase( RNLP) was noticed to be inhibited via the test antibiotic suggesting its bactericidal action. The maximum concentration was 7-8 mcg/ ml at a maximum time of 2 hours when 600 mg dose was orally administered in randomized human clinical trials phases 1/2, and T1/2 reached 2.5 hours following first-order kinetics of elimination. The duration of its action was nearly 12 hours after oral administration. Rare toxicity was detected during preclinical and randomized human clinical trials phases 1/2 in the form of mild diarrhea and cholestatic jaundice in less than 5 % of experimental candidates.
Conclusion:
The present study was promising due to the bactericidal antibiotic Myxopyronin A production from Myxococcus fulvus 124B02 isolated from different soil environments in Egypt.
Biology and Life Sciences, Immunology and Microbiology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
